Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the effects of pemetrexed on mesothelioma and non-small cell lung cancer patients with fluid around their lungs or abdomen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Pemetrexed

Criteria

Inclusion Criteria:

• Diagnosis of locally advanced or metastatic (Stage III or IV at entry) non-small cell lung cancer (NSCLC) or mesothelioma

• Presence of third-space fluid (fluid around the lungs or abdomen).

• Eastern Cooperative Oncology Group Performance Status of 0 or 1.

• Prior anticancer treatment (except radiation) must be completed at least 3 weeks prior to study enrollment, and the patient must have recovered from the sharp toxic effects the anticancer treatment.

• Estimated life expectancy of at least 8 weeks.

Exclusion Criteria:

• Have received treatment within the last 30 days with a drug that was not a marketed product.

• Active infection that, in the opinion of the investigator, would not allow the patient to tolerate therapy.

• Pregnancy.

• Breast-feeding.

• Significant weight loss (that is, greater than or equal to 10% of body weight) over the 6 weeks before study entry.

• Brain metastases.